Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Methotrexate
Sandoz Pty Ltd
Medicine Registered
________________________________________________________________________________ Methotrexate Ebewe Methotrexate Ebewe_CMI_v2_042012_clean.doc0412 Page 1 of 4 METHOTREXATE EBEWE _Methotrexate (Meth-o-TREX-ate) _ CONSUMER MEDICINE INFORMATION _ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Methotrexate Ebewe. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking Methotrexate Ebewe against the benefits this medicine is expected to have for you. This medicine is likely to be used while you are at the clinic or in hospital. If possible, please read this leaflet carefully before this medicine is given to you. In some cases this leaflet may be given to you after the medicine has been used. If you have any concerns about taking this medicine, ask your doctor or pharmacist. For any further information please see your doctor or pharmacist Keep this leaflet. You may need to read it again _ _ _ _ WHAT METHOTREXATE EBEWE IS USED FOR Methotrexate Ebewe belongs to a group of anticancer drugs known as antineoplastics. Methotrexate Ebewe works by preventing the growth of certain cells. It is used for different types of cancer and also severe psoriasis (a skin condition). Methotrexate Ebewe may be used for the treatment of other conditions that are not mentioned above. Your doctor will be able to tell you about the specific condition for which you have been prescribed Methotrexate Ebewe. This medicine is available only with a doctor's prescription. Methotrexate is not recomm Read the complete document
_Product information _ _ _ _ Page 1 _ _Methotrexate Ebewe 500mg/5mL, 1000mg/10mL, 5000mg/50mL concentrated injection _ _04/2012 _ _Sandoz Pty Ltd _ _ _ _ Version 04 _ PRODUCT INFORMATION_ _ METHOTREXATE EBEWE ® 500MG/5ML, 1000MG/10ML, 5000MG/50ML CONCENTRATED INJECTION VIAL WARNINGS METHOTREXATE EBEWE (METHOTREXATE 100 MG/ML) IS RECOMMENDED FOR INTRAVENOUS ADMINISTRATION ONLY. METHOTREXATE MUST BE USED ONLY BY DOCTORS EXPERIENCED IN ANTIMETABOLITE CHEMOTHERAPY OR IN THE CASE OF NON- ONCOLOGICAL CONDITIONS, BY A SPECIALIST DOCTOR. BECAUSE OF THE POSSIBILITY OF FATAL OR SEVERE TOXIC REACTIONS THE PATIENT SHOULD BE FULLY INFORMED BY THE DOCTOR OF THE RISKS INVOLVED AND SHOULD BE UNDER HIS CONSTANT SUPERVISION. DEATHS HAVE BEEN REPORTED WITH THE USE OF METHOTREXATE. IN THE TREATMENT OF PSORIASIS, METHOTREXATE USE SHOULD BE RESTRICTED TO SEVERE, RECALCITRANT, DISABLING DISEASE THAT IS NOT ADEQUATELY RESPONSIVE TO OTHER FORMS OF THERAPY, AND ONLY WHEN THE DIAGNOSIS HAS BEEN ESTABLISHED, BY BIOPSY AND/OR AFTER APPROPRIATE CONSULTATION. 1. Methotrexate may produce marked depression of the bone marrow, anaemia, aplastic anaemia, leucopenia, neutropenia, thrombocytopenia and bleeding. 2. Methotrexate may be hepatotoxic, particularly at high dosage or with prolonged therapy. Liver atrophy, necrosis, cirrhosis, fatty changes and periportal fibrosis have been reported. Since changes may occur without previous signs of gastrointestinal or haematological toxicity, it is Read the complete document